Condition

Unresectable Hepatocellular Carcinoma clinical trials and research

• 17Clinical trials
• 7Countries

Newest Unresectable Hepatocellular Carcinoma clinical trials

All recruiting trials (17)

• First-line combo therapy with anlotinib, benmelstobart, and HAIC for unresectable HCC

  This study tests whether adding benmelstobart and hepatic arterial infusion chemotherapy to anlotinib can help people with unresectable hepatocellular carcinoma respond to treatment as a first line.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07806292

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

• Combined immunotherapy and stereotactic radiotherapy to shrink unresectable liver cancer for possible surgery

  This project will test whether stereotactic body radiotherapy followed by immunotherapy can shrink unresectable hepatocellular carcinoma so surgery becomes possible for adults with preserved liver function.

  Recruiting The University of Hong Kong · Hong Kong · NCT07305428

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• Emotional stress and immunotherapy outcomes in liver cancer

  This study will see if emotional distress changes how well immunotherapy works for people with hepatocellular carcinoma.

  Recruiting at 5 sites Guilin Medical University, China · Zhanjiang, Guangdong and 4 other locations · NCT07141056

• Evaluating a combination treatment for advanced liver cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it helps patients live longer and feel better.

  Recruiting Phase 1/2 Seoul National University Hospital · Seoul · NCT06911255

• Comparing two treatments for advanced liver cancer

  This study is testing whether a new treatment using yttrium-90 carbon microspheres works better than the standard chemoembolization for people with advanced liver cancer.

  Recruiting Zhongda Hospital · Nanjing, Jiangsu · NCT06909708

• Collecting data on treatment effectiveness and safety for patients with advanced liver cancer

  This study is testing how well a combination of a specific cancer treatment and immunotherapy works for patients with advanced liver cancer who haven't been treated before or have had their cancer come back.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06788353

• Combining TACE with Camrelizumab and Apatinib for Liver Cancer

  This study is testing if combining a liver cancer treatment called TACE with two drugs, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better compared to standard treatments.

  Recruiting Phase 3 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06485466

• Combining immune and anti-angiogenic therapies for advanced liver cancer treatment

  This study is testing three different combinations of immune and anti-cancer treatments to see which one works best for people with advanced liver cancer that can't be surgically removed.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06360042

• Effect of Splenectomy on Treatment for Unresectable Liver Cancer

  This study is testing if removing the spleen can help improve treatment outcomes for patients with advanced liver cancer who also have cirrhosis by using a combination of targeted therapy and immunotherapy.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06280313

• Combining radiation therapy with immunotherapy and targeted therapy for liver cancer

  This study is testing whether combining a type of radiation therapy with two cancer drugs can help people with hard-to-treat liver cancer live longer without their disease getting worse.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05917431

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Combining atezolizumab with a multi-kinase inhibitor for advanced liver cancer treatment

  This study is testing if adding atezolizumab to either cabozantinib or lenvatinib can help people with advanced liver cancer live longer and feel better compared to just taking the multi-kinase inhibitor alone.

  Recruiting at 10 sites Phase 2 Academic and Community Cancer Research United · Scottsdale, Arizona and 15 other locations · NCT05168163

• Combining Atezolizumab, Bevacizumab, and Radiation for Unresectable Liver Cancer

  This study is testing if combining two cancer-fighting drugs with targeted radiation can help people with liver cancer that can't be surgically removed.

  Recruiting at 2 sites Phase 1 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT05096715

• Using modified immune cells and a vaccine to treat unresectable liver cancer after radiation therapy

  This study is testing a new way to treat liver cancer that can't be removed by surgery by using modified immune cells and a vaccine after radiation therapy to see if it helps patients feel better.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT03942328

Related topics

Quick answers

How many Unresectable Hepatocellular Carcinoma clinical trials are recruiting right now?

17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in China (10 trials), United States (5 trials), Japan (2 trials), South Korea (1 trial), Hong Kong (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 5, Phase 2: 4, Phase 3: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →